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Abstract
Background: Bacterial vaginosis increases the risk of spontaneous preterm delivery at less than 34 weeks of
gestation.
Objective: The purpose of this study was to evaluate the efficacy of the early administration of selected lactobacilli
strains (probiotics) to pregnant women with asymptomatic bacterial vaginosis/intermediate-degree infections to
prevent spontaneous premature delivery and associated neonatal morbidity.
Methods/Design: Asymptomatic pregnant women at less than 20 weeks of gestation, with no indication of
elective preterm delivery, with a vaginal pH ≥ 4.5 and Nugent score > 3 were randomly assigned to the placebo
or intervention group (oral administration of selected lactobacilli up to the 24th to 26th week of gestation). The
randomisation was stratified for the history of premature delivery (HPD) and blocked. The allocation was concealed,
and the participating health professionals and patients were blinded. The primary outcome was preterm delivery
(<34 to <32 weeks), and the secondary outcomes were associated neonatal complications.
Results: In total, 4,204 pregnant women were screened; 320 and 324 individuals were respectively randomly
assigned to the placebo and intervention groups, and 62% finished the trial. None of the randomised patients
were lost to follow-up. For the non-HPD stratum, the intent-to-treat relative risks of spontaneous premature birth at
< 34 and < 37 weeks’ gestation were 0.33 (0.03, 3.16) and 0.49 (0.17, 1.44), respectively, and they were non-
significant (ns) with p = 0.31 and 0.14. The corresponding actual treatment figures were zero and 0.32 (0.09, 1.19),
which were ns with p = 0.12 and 0.06. The intent-to-treat relative risk of spontaneous premature birth at < 37
weeks of gestation for the trial as a whole, including HPD and non-HPD participants, was 0.69 (0.26, 1.78), p = 0.30
(ns). The neonatal complications under evaluation occurred in only one infant (< 34 weeks; placebo group) who
presented with respiratory distress syndrome and suspected early neonatal sepsis. The recorded adverse events
were minor and relatively non-specific.
Conclusions: The efficacy of the tested probiotics to prevent preterm delivery among women without a history of
preterm delivery was not determined because the study sample was insufficient to estimate statistically significant
intent-to-treat effects; additional studies are needed to evaluate this intervention among these women.
Trial registration: Trial registration at NIH register: NCT00303082. Sources of funding: the Brazilian Health Ministry
and the State of Rio de Janeiro Research Foundation.
* Correspondence: leticiak@ensp.fiocruz.br
1Health Technology Assessment Unit, National School of Public Health,
Oswaldo Cruz Foundation, Brazilian Health Ministry, Brazil, R. Leopoldo
Bulhões, 1480, Rio de Janeiro, 21041-210, Brazil
Full list of author information is available at the end of the article
Krauss-Silva et al. Trials 2011, 12:239
http://www.trialsjournal.com/content/12/1/239 TRIALS
© 2011 Krauss-Silva et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Keywords: spontaneous preterm delivery, prevention, randomised controlled parallel-group trial, probiotics, history
of preterm delivery
1- Background
High rates of preterm delivery, i.e., above 10%, remain
prevalent in developing and developed regions around
the world; preterm birth is associated with nearly 80%
of foetal, neonatal, and infant deaths [1-3].
Approximately 25% of preterm deliveries occur as the
result of medical indications, and the remaining cases
occur spontaneously [4]. Spontaneous preterm deliveries
that occur prior to 35 weeks of gestation, and before the
32
nd week in particular, have been strongly associated
with intrauterine infections, including bacterial vaginosis
(BV) [5,6]. A history of preterm delivery (HPD) is the
most important factor in spontaneous preterm delivery;
HPD increases the risk of a subsequent preterm delivery
by threefold and is likely associated with underlying risk
factors [4,7,8]. Important risk factors for spontaneous
preterm delivery, such as age < 18 years, race, education,
and bacterial vaginosis, are associated with a low socioe-
conomic status. BV doubles the risk of preterm delivery
prior to 35 weeks of gestation [7]. BV is present in 15-
20% of normal pregnant women in developed countries
[7], and this proportion is almost twice as high in high-
risk populations [9].
Prematurity resulting from intrauterine infections
increases the probability of complications, including
early sepsis, bronchopulmonary dysplasia, periventricular
leukomalacia, and necrotising enterocolitis [10-13],
which may cause long-term neurological disabilities and
death.
Bacterial vaginosis (BV) is a modification of the vaginal
flora that is characterised by a diminished or absent flora
of lactobacilli, which increases the vaginal pH and leads
to a significantly increased colonisation by several anae-
robic or facultative microorganisms, including Gardener-
ella vaginalis, Prevotella sp., Bacteroides sp., Mobiluncus
sp., Gram-positive cocci, and genital mycoplasma [14].
The association between infections of the upper geni-
tal tract and preterm delivery (premature birth) in BV
asymptomatic women formed the basis of several trials
using antibiotics to prevent preterm delivery in these
women; the results of these trials have been contradic-
tory [15-17]. The results of a very large, well-designed
trial did not indicate any clear benefit of antibiotic ther-
apy; in addition, the study showed negative results in
the subgroup of patients with a history of preterm deliv-
ery [18]. Bacterial resistance, timing of the intervention
(possibly delayed), and foetal inflammatory syndrome,
which can result in early intrauterine death, could help
explain such results [19-21].
The study presented here tested an alternative to anti-
biotics, i.e., so-called probiotics (a type of bacterial ther-
apy), to prevent preterm delivery associated with
intrauterine infections originating from bacterial vagino-
sis. Probiotics have been tested mainly for treating infec-
tious, inflammatory, and allergic conditions that occur
in the intestinal, genitourinary, and respiratory tracts
[22-24]. Many of the effects of probiotics are not related
solely to changes in the microbiota, as indicated by cul-
tivation experiments; rather, many of the beneficial
effects of probiotics are related to their immune-modu-
lating effects (i.e., increases in both immunologic and
anti-inflammatory activity) [25]. The rationale for the
trial presented here was the manipulation of vaginal
microbiota to interrupt the infectious/inflammatory pro-
cess that leads to preterm delivery.
Four small trials have tested the efficacy and safety of
selected probiotics (generally, Lactobacillus rhamnosus
GR-1 associated with Lactobacillus fermentum TC-14)
for curing urogenital infections, including BV, in asymp-
tomatic non-pregnant women [26-30]. Oral treatments
of more than one million of each selected bacillus,
administered once or twice daily for 2-8 weeks, showed
an efficacy for curing BV (Nugent score) of at least 40%,
which was statistically significant. The best results corre-
sponded to the highest dose regimen; most of the treat-
ment effect remained one month after the end of the
treatment. No adverse events were reported. However,
there is no evidence of the efficacy of probiotics to pre-
vent BV-related conditions, such as preterm delivery
and neonatal morbidity.
2. General Objectives
To estimate the efficacy of the early administration of
specially formulated probiotics to pregnant women with
bacterial vaginosis or intermediate-degree infection to
prevent the occurrence of spontaneous premature deliv-
ery and related neonatal mortality and morbidity.
2.1. Specific objectives
a- To assess the presence of bacterial vaginosis and
intermediate-degree infections in asymptomatic preg-
nant women with no risk/indication of elective preterm
delivery who were admitted to prenatal care after the 8
th
and before the 20
th week of gestation.
b- To investigate whether the study intervention can
reduce the vaginal pH and the Nugent score.
c- To assess the efficacy of an early intervention with
special probiotics to treat bacterial vaginosis/
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neous preterm delivery and associated neonatal condi-
tions in positive women, according to item a,b y
conducting a controlled, randomised, patient-allocator-
physician/nurse-evaluator-blind trial.
3. Methodology
A detailed version of the trial protocol was presented in
a previous paper [31].
Asymptomatic pregnant women who were admitted
after the 8
th and before the 20
th week of pregnancy in
selected public prenatal services in the city of Rio de
Janeiro were evaluated to identify a) excluding clinical
conditions associated with elective preterm delivery,
symptomatic vaginal conditions, and the recent use of
corticotherapy or antibiotic therapy and b) pregnant
women with a previous history of preterm delivery.
Gestational age was determined by ultrasound in 71%
of the randomised women; in 29% of the randomised
women, only the date of the last menstrual period was
available upon admission to the trial.
Women who tested positive for syphilis, toxoplasmo-
sis, gonorrhoea, or HIV were excluded. Women report-
ing vaginal discharge were excluded only if a vaginal
smear analysis showed bacterial vaginosis, trichomonia-
sis, or candidiasis; women with macroscopic genital
lesions or microscopic pre-cancerous HPV-related
lesions were excluded.
The additional exclusion criteria were applied: multi-
ple gestation, cervical incompetence (cerclage in current
gestation), and clinical suspicion of a lower urinary tract
infection.
After written informed consent was obtained, a vaginal
pH assessment was performed; patients with pH < 4.5
were excluded. A cervicovaginal smear was then
obtained to evaluate the presence of BV or an inter-
mediate-degree infection using the Nugent method [32].
Women with Nugent scores < 4 were excluded from the
trial.
Randomisation and Blinding
Randomisation was stratified according to the history of
premature delivery (HPD) and blocked.
The sequences for randomisation were electronically
generated by an independent research assistant who
produced one blocked and randomised list for each stra-
tum using a permuted block design. After written
informed consent was obtained, women with Nugent
scores > 3 were randomly assigned to receive capsules
of either a placebo or probiotics, which were identical in
appearance, in sequentially numbered identical contain-
ers according to the allocation sequence. Research
nurses responsible for the allocation were not directly
involved with prenatal care, i.e., with clinical screening.
Physicians/nurses and researchers/evaluators were also
blinded to the randomisation process.
Intervention
The trial tested two lactobacilli strains, Lactobacillus
rhamnosus GR-1 and Lactobacillus reuteri RC-14, that
w e r ed e v e l o p e da n ds t u d i e db yR e i de ta l .[ 2 6 - 3 0 ] .E a c h
capsule contained more than one million bacilli of each
strain. The participants were instructed to take two cap-
sules per day up until approximately the 24
th-26
th week
of gestation; the treatment duration varied from six to
twelve weeks depending on the participant’s gestational
age at the time of enrolment in the study.
Compliance/adherence, adverse events, and clinical
intercurrences were monitored by the research nurse at
each routine prenatal visit until the completion of the
treatment. Adherence was defined as at least 6 weeks of
treatment with ingestion of at least 80% of the pre-
scribed dose. At the post-treatment prenatal care visit,
vaginal pH was assessed; a cervicovaginal smear and
fluid were obtained to the evaluate changes in these
parameters.
The primary outcome was spontaneous preterm deliv-
ery between 34 and 37 weeks’ gestation. Associated
morbidities, early neonatal sepsis, respiratory distress
syndrome, bronchopulmonary dysplasia, periventricular
leukomalacia, necrotising enterocolitis, and retinopathy
of prematurity were the secondary outcomes. The defi-
nitions of these conditions were similar to those used by
the Vermont-Oxford Network [33].
Sample size
The estimated prematurity rate for deliveries at < 34
weeks was 6%; the estimated efficacy was 50%. With a
5% significance level, one- and two-sided tests, and 80%
power to detect differences in the premature birth rates
between the intervention and placebo groups, the trial
sample size was estimated to be 1,140 and 1,480,
respectively.
4. Results
Flow of patients
Figure 1 shows the flow of patients according to the pro-
tocol and the latest CONSORT guidelines [34-36]. In
total, 4,204 pregnant women were screened for the
selected clinical conditions; 1,506 were excluded for one
or more of the following conditions: hypertension, dia-
betes, asthma, cervical incompetence, atypical vaginal
bleeding, atypical vaginal secretion, HPV, gonorrhoea,
syphilis, dysuria, pruritus, burning, corticotherapy, recent
antibiotic therapy (within 8 weeks prior to screening), or
other miscellaneous clinical factors. Of the remaining
patients, 381 pregnant women were not eligible because
their gestational age was 20 weeks or greater; 202 were
Krauss-Silva et al. Trials 2011, 12:239
http://www.trialsjournal.com/content/12/1/239
Page 3 of 11not eligible at the first visit because their gestational age
was less than 8 weeks, and they were not available during
subsequent prenatal visits; 28 women could not provide
the date of their last menstrual period and did not pre-
sent an ultrasound test; and 233 individuals refused con-
sent for the first phase of the trial.
Vaginal pH was determined for 1,854 women: 546 had
pH < 4.5 and were excluded. Of the pH-eligible women,
554 had Nugent scores < 4 and were excluded. Six
women refused consent for the intervention phase of
the trial. Of the women who were then eligible for ran-
domisation and provided consent, 104 were not
Figure 1 Observed flow of patients in the trial. * Returned all capsules (lack of adherence), unknown reason. ** Returned all capsules
(unknown reason) (3), family opposed participation in the trial (1), pregnant woman suffered abortion (1), participant presented with UTI (1); the
last two events occurred on the day that they were randomly assigned. *** Randomisation error (3): Nugent score < 4 (2); gestational age
miscalculation (1). **** Randomisation error (1): Nugent score < 4.
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or presented with excluding conditions at the prenatal
care/randomisation visit (particularly hypertension and
symptomatic vaginal infection). Finally, 644 women were
randomly assigned, with 324 allocated to the interven-
tion group and 320 placed into the placebo group. Of
these women, 9 did not start treatment, 318 initiated
treatment with probiotics, and 317 began taking the
placebo.
After the initial treatment, 120 women in the placebo
group and 122 in the treatment group discontinued the
intervention: a) 4 women were excluded from the pla-
cebo group (3 women because of pregnancy-induced
hypertension and 1 individual was overweight), and 7
were excluded from the treatment group (1 case of
umbilical hernia and thrombocytopenia, 4 cases of preg-
nancy-induced hypertension, 1 case of low platelet
count, and 1 instance of a high risk of thrombosis);
these patients were referred to high-risk care; b) 59 par-
ticipants from the placebo group and 46 women from
the treatment group required antibiotic therapy and dis-
continued intervention; and c) 57 women in the placebo
group and 69 women in the treatment group were non-
adherent. Nearly 62% of the participants finished the
trial; none of the randomised participants were lost to
follow-up.
Outcomes
Four patients were excluded from the analysis: 3 from
the placebo group (randomisation errors: Nugent score
< 4, two patients; gestational age miscalculation, one
patient) and 1 from the treatment group (randomisation
error: Nugent score < 4).
Only 35 randomly assigned women, or 5%, had a his-
tory of premature delivery (HPD). Tables 1 and 2 pre-
sent the post-randomisation distribution of the relevant
variables for the intervention and placebo groups of
each stratum of women with and without a history of
premature delivery (HPD; NHPD). The distribution of
risk variables between the treatment groups of the non-
HPD pregnant women was balanced. The distribution of
risk variables among the HPD participants was balanced,
except for Nugent scores > 8, which were twice as fre-
quent in the intervention group as in the placebo group
(ns).
The outcomes were analysed according to intent-to-
treat and actual treatment (explanatory analysis); addi-
tional analyses were also performed, and Table 3 pro-
vides details on the corresponding denominators, i.e.,
which participants were included in each analysis. Of 35
HPD women, two participants from the intervention
group delivered premature infants (Table 3). For the
non-HPD stratum, the following denominators were
observed: a) the rates of spontaneous deliveries at < 34
and < 37 weeks of gestation were less than 1% and 2.5%,
respectively; no infant was born at less than 30 weeks of
gestation; b) the intent-to-treat relative risks of sponta-
neous premature birth at < 34 and < 37 weeks of gesta-
tion were 0.33 (0.03, 3.16) and 0.49 (0.17, 1.44),
respectively, which were non-significant (ns) with p =
0.31 and 0.14, (Table 3). Additionally, c) the correspond-
ing actual treatment figures were zero and 0.32 (0.09,
1.19), respectively, which were ns with p = 0.12 and 0.06
(Fisher’s exact test, one tail) (Table 3). The intent-to-
treat relative risk of spontaneous premature birth at <
37 weeks of gestation for the trial as a whole, including
HPD and NHPD participants, was 0.69 (0.26, 1.78),
which was ns with p = 0.30, and the corresponding
actual treatment figure was 0.54 (0.19, 1.60), which was
ns with p = 0.20 (Fisher’s exact test, one tail).
Among the spontaneous preterm babies with < 37
weeks of gestation, targeted neonatal complications
occurred in only one infant with < 34 weeks of gestation
from the placebo group, who presented with respiratory
distress syndrome and suspected early neonatal sepsis.
The recorded adverse events were minor and relatively
non-specific; their frequency was low in both trial arms.
The frequencies of such events in the intervention and
placebo groups was as follows: nausea (5 intervention; 8
placebo), vomiting (6;4), diarrhoea (3;4), sleepiness (0;2),
headache (4;1), pyrosis (1;3), stomach ache (2;0), uterine
contractions (2;0), nausea/vomiting and headache (1;3 ),
vomiting and diarrhoea (1;1), pruritus (0;3), abdominal
pain and fainting (1;0), dizziness (1;1), abdominal ache
(2;0), abdominal pain and vomiting (1;0), bloody diar-
rhoea (1;0), and tachycardia (1;1). One maternal death
occurred in the placebo group; according to the Com-
mittee on Maternal Deaths of the State Health Depart-
ment, the maternal death was caused by the syndrome
of haemolytic anaemia, elevated liver enzymes, and a
low platelet count (HELLP syndrome).
5. Conclusions
The efficacy of the administration of the tested probio-
tics at the early second trimester in preventing sponta-
neous preterm delivery at < 37 weeks of gestation
among women without a history of preterm delivery
was not determined because the study sample was insuf-
ficient to estimate statistically significant intent-to-treat
effects; additional studies are necessary to evaluate this
intervention among these women.
6. Discussion
The findings of this trial lacked a sufficient sample size,
as indicated by the p values, to permit reliable inferences
concerning the efficacy of the tested probiotics in pre-
venting spontaneous premature births. However, all
point estimates of relative risks for the non-HPD
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Page 5 of 11Table 1 Post-randomization distribution of relevant risk variables according to treatment group for the stratum of
women without history of premature delivery (NHPD)
Placebo Treatment Total
Factor Frequency % Mean Frequency % Mean Frequency % Mean
Gestacional Age at
Randomization
< 12w 9 3.0% 11w.2d 4 1.3% 11w.4d 13 2.1% 11w.2d
(12w-16w) 103 34.1% 14w.2d 115 37.5% 14w.3d 218 35.8% 14w.2d
(16w-20w) 190 62.8% 18w.6d 186 61.2% 18w.3d 376 61.70% 18w.5d
>20w* 2 0.7% 21w.3d 0 0.0% - 2 0.3% 21w.3d
Total 304 100.0% 17w.1d 305 100.0% 16w.6d 609 100.0% 16w.7d
Nugent Score
<4 2 0.7% 2.5 1 0.3% 1.0 3 0.5% 2.0
4-6 81 26.6% 5.4 90 29.5% 5.4 171 28.1% 5.4
7-8 181 59.5% 7.6 173 56.7% 7.6 354 58.5% 7.6
9-10 40 13.2% 9.2 41 13.4% 9.4 81 13.3% 9.3
Total 304 100.0% 7.2 305 100.0% 7.2 609 100.0% 7.2
Lag between elegible
Nugent score and
randomization
< = 2 weeks 180 59.2% 1w.3d 184 60.3% 1w.1d 364 59.8% 1w.2d
>2 weeks 124 40.8% 3w.1d 121 39.7% 3w.3d 245 40.2% 3w.2d
Total 304 100.0% 2w.1d 305 100.0% 2w.0d 609 100.0% 2w.0d
pH
4.5 90 29.6% 4.50 81 26.6% 4.50 171 28.1% 4.50
5.0 151 49.7% 5.00 156 51.1% 5.00 307 50.4% 5.00
5.5 or 6.0 63 20.7% 5.52 68 22.3% 5.54 131 21.5% 5.53
Total 304 100.0% 4.96 305 100.0% 4.99 609 100.0% 4.97
Age (years)
<18 41 13.5% 16.4 39 12.8% 16.4 80 13.1% 16.4
> = 18 263 86.5% 24.8 266 87.2% 24.6 529 86.9% 24.7
Total 304 100.0% 23.7 305 100.0% 23.6 609 100.0% 23.6
Height (m)
< = 1.55 83 27.3% 1.52 72 23.6% 1.52 155 25.5% 1.52
>1.55 221 72.7% 1.63 233 76.4%1 1.63 454 74.5% 1.63
Total 304 100.0% 1.60 305 100.0% 1.60 609 100.0% 1.60
Ethnicity
White 105 34.5% 103 33.8% 208 34.2%
Black 199 65.5% 200 65.6% 399 65.5%
NA 0 0% 2 0.7% 2 0.3%
Total 304 100.0% 305 100.0% 609 100.0%
Nulliparity
No 109 35.9% 115 37.7% 224 36.8%
Yes 195 64.1% 190 62.3% 385 63.2%
Total 304 100.0% 305 100.0% 609 100.0%
Adherence
No 107 35.2% 104 34.1% 211 34.6%
Yes 197 64.8% 201 65.9% 398 65.4%
Total 304 100.0% 305 100.0% 609 100.0%
*Randomization errors: one error was related to the determination of gestational age and 3 errors were related to the assessment of the Nugent score.
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were less than 0.5.
Although the number of screened women was higher
than estimated, the planned sample size, based on avail-
able international and national/local information, was
not attained because the attrition rates were high. The
trial had to be interrupted mainly because of a lack of
on-going financial support. The main sources of attri-
tion were the higher-than-expected prevalence of clini-
cal, vaginal pH, and Nugent exclusion conditions. In
addition, the intent-to-treat effect was likely diminished
because a significant proportion of the randomised
women exhibited conditions that required antibiotic
therapy after the initiation of treatment (such as symp-
tomatic vaginal discharge and urinary tract infection);
this problem was more frequent in the placebo group
and led to a discontinuation of the treatment. The
intent-to-treat effect was also affected by a higher-than-
expected lack of adherence, which was more frequent in
the intervention group. Several randomly assigned
women were excluded and discontinued treatment
because they suffered abortion or developed conditions
for exclusion that were strongly associated with the indi-
cation of preterm delivery, such as hypertension, and
were referred to high-risk care (Figure 1). However,
these women were considered in the intent-to-treat
analyses.
The participants were instructed to take the treat-
ment/placebo until approximately the 24
th-26
th week of
gestation. By this time, at the end of the second trime-
ster, BV is less likely to occur and commonly remits;
however, the main concern was to avoid delivery at < 34
weeks, and an eventual re-infection and progression
would take approximately 8 weeks to occur [9].
Three out of five women who spontaneously delivered
prior to the 34
th week of gestation exhibited initial
Nugent scores of 9 or 10; these scores were present in
less than 15% of the total number randomised women,
which is consistent with the hypothesis that BV is a risk
factor for premature birth in the study population
[8,37-39].
Four out of five spontaneous deliveries at < 34 weeks
of gestation were initiated with the preterm premature
rupture of membranes (PPROM); only one woman was
admitted for premature labour without PPROM. These
5 cases could be associated with intrauterine infection,
including BV [20,40-43]. The non-PPROM case was not
associated with any recorded maternal or foetal condi-
tion, other than BV, that can cause PD. Two cases of
PPROM were associated with oligohydramnios; such an
Table 2 Post-randomisation distribution of risk variables and adherence according to treatment group for women
with a history of premature delivery (HPD)
Placebo Treatment Total
Factor Frequency % Mean Frequency % Mean Frequency % Mean
Gestacional Age at
Randomization
< 12w 2 12.5% 11w.6d 2 10.5% 11w.1d 4 11.4% 11w.4d
(12w-16w) 7 43.8% 14w.3d 7 36.8% 14w.3d 14 40.0% 14w.3d
(16w-20w) 7 43.8% 17w.5d 10 52.6% 19w.4d 17 48.6% 18w.6d
Total 16 100.0% 15w.4d 19 100.0% 16w.5d 35 100.0% 16w.2d
Nugent Score
4-6 5 31.3% 4.8 5 26.3% 5.4 10 28.6% 5.1
7-8 9 56.3% 7.8 9 47.4% 7.7 18 51.4% 7.7
9-10 2 12.5% 9.0 5 26.3% 9.0 7 20.0% 9.0
Total 16 100.0% 7 19 100.0% 7.4 35 100.0% 7.2
Height(m)
< = 1.55 4 25.0% 1.51 5 26.3% 1.53 9 25.7% 1.52
>1.55 12 75.0% 1.64 14 73.7% 1.63 26 74.3% 1.63
Total 16 100.0% 1.61 19 100.0% 1.60 35 100.0% 1.60
Ethnicity
White 3 18.8% 5 26.3% 8 22.9%
Black 13 81.2% 14 73.7% 27 77.1%
Total 16 100.0% 19 100.0% 35 100.0%
Adherence
No 4 25.0% 7 36.8% 11 31.4%
Yes 12 75.0% 12 63.2% 24 68.6%
Total 16 100.05 19 100.0% 35 100.0%
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One case of PPROM occurred in a woman with HPD,
and the remaining case of PPROM was not associated
with any recorded maternal or foetal condition, other
than BV, that could cause PPROM and PD [43].
Because HPD is considered to be a major predictor of
subsequent PD, including very premature births [43],
women were stratified for HPD and randomly assigned
with a stratum-specific randomisation list. The number
of HPD women enrolled in the trial was relatively small
(35 cases); the corresponding intervention arm received
more severe cases of BV than the placebo arm (Table
2). Table 3a, which shows the related outcomes, has two
blank cells that indicate missing data, which prevents
any meaningful analysis. Furthermore, the fact that such
HPD cases are generally considered especially difficult
to understand and solve [7,42] prompted the authors to
analyse the data from the non-HPD group separately.
Table 3 Outcome Analyses
3.1. Premature deliveries related to HPD pregnant women, according to randomization group and adherence
PLACEBO Treatment
Adherent No-adherent Exclusion (ATB) Adherent No-adherent Exclusion(ATB) Total
PD<34w. 0 0 0 1 0 0 1
PD<37w. 0 0 0 2 0 0 2
NPD 11 0 5 9 4 4 33
Total 11 0 5 11 4 4 35
PD: Premature Delivery
NPD:Non-premature delivery
3.2. Relative risk of premature delivery related to NHPD pregnant women - Intent-to-treat analysis *
Placebo Treatment RR RR 95% CI p**
PD<34w. 3 1 0.330 (0.03,3.16) 0.31
PD<37w. 10 5 0.495 (0.17,1.43) 0.14
Total(denominator)* 301 304
*Randomisation errors were not included.
3.3. Relative risk of premature delivery related to NHPD pregnant women - Exploratory analysis
(actual treatment)*
Placebo Treatment RR RR 95% CI p**
PD<34w. 3 0 0.000 - 0.12
PD<37w. 9 3 0.326 (0.09, 1.19) 0.06
Total (denominator)* 188 192
* Not included: randomization errors, those who did not receive intervention, post- randomisation exclusions, those who discontinued treatment
due to antibiotics prescription, and those who were not adherent.
Additional Analysis (1)
3.4. Relative risk of premature delivery related to NHPD pregnant women
Placebo Treatment RR RR 95% CI p**
PD<34w. 3 1 0.333 (0.03, 3.19) 0.31
PD<37w. 10 5 0.500 (0.17, 1.44) 0.15
Total (denominator)* 297 297
*Not included: randomization errors and post-randomisation exclusions
Additional Analysis (2)
3.5. Relative risk of premature delivery related to NHPD pregnant women*
Placebo Treatment RR RR 95% CI p**
PD<34w. 3 0 0.000 0.12
PD<37w. 9 3 0.323 (0.09, 1.18) 0.06
Total (denominator)* 241 249
* Not included: randomisation erros, those who did not receive intervention, post-randomisation exclusions, and those who discontinued treatment
due to the prescription of antibiotics.
** Fisher’s exact test, one tail.
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method for determining gestational age. Two premature
infants had ultrasound-determined gestational ages of 30
6/7 and 32 4/7 weeks, which were different from the
gestational ages estimated by the attending neonatolo-
gists (33 6/7 and 30 6/7 weeks, respectively). However,
none of the premature infants were born before the 30
th
week, which is consistent with the relatively low rate of
observed morbid events and the birth weights in the
study.
Neonatal records were reviewed by two research neo-
natologists. All 5 infants spontaneously delivered at less
than 34 weeks of gestation were discharged from the
hospital. Of these five cases, only one newborn was
diagnosed with any of the morbid conditions under
study; that infant, whose mother belonged to the pla-
cebo group and non-HPD stratum, presented with
pneumonia as well as possible respiratory distress syn-
drome and sepsis (Table 3). Pneumonia was diagnosed
based on the presence of risk factors for infection, clini-
cal signs, and radiographic findings. Given that radio-
graphic findings in pneumonia can be identical to those
of hyaline membrane disease [44], it was not possible to
dismiss HMD in the immediate postpartum period in
this case. Sepsis was suspected because of an immature-
to-total neutrophil ratio higher than 0.2, although a
blood culture was not positive, as required by the Ver-
mont Oxford Network criteria. Other sources consider
an immature-to-total neutrophil ratio higher than 0.2 to
be an equally or more accurate criterion for early sepsis
compared with a positive blood culture result [44]. The
infant progressed well and did not develop bronchopul-
monary dysplasia.
Interestingly, the case with delivery at < 34 weeks of
gestation, in which the Nugent score decreased from 9
to 2 by the end of the trial (normal vaginal mucosa),
was an adherent woman with history of preterm delivery
from the intervention arm who initiated treatment after
the 20
th week of pregnancy. It has been argued that
HPD is caused by chronic intrauterine infection [45].
One explanation is that lactobacilli that colonise the
vagina of such women, and of women with repeated BV,
produce an insufficient amount of lactic acid and other
bactericidal substances [46,47]. In addition, the gesta-
tional age at which the vaginal infection occurs and
treatment/intervention begins may interact with the
maternal and foetal immune-genetic profile/response to
result in birth at less than 34 weeks of gestation [48-51].
After the 20
th week of gestation, the infection may have
progressed to the extent that an undesired outcome
could be determined [5,19].
To better understand the significance of the outcomes
in the present trial, the early (early mid-trimester) and
later (late mid-trimester) cervical immune-genetic
profiles (i.e., selected cytokines and related genetic poly-
morphisms) of the randomised women are currently
being analysed and may be helpful in dismissing or rein-
forcing the biological plausibility and, therefore, the pro-
spects for a positive role of probiotics in the prevention
of spontaneous premature births associated with bacter-
ial vaginosis.
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